Cargando…

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

BACKGROUND: Cyclophosphamide plus thalidomide as induction for multiple myeloma patients eligible for autologous stem cell transplantation may be a limiting factor for cell mobilization. The minimum acceptable mobilized peripheral blood stem cell count to prevent deleterious effects during transplan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crusoe, Edvan de Queiroz, Higashi, Fabiana, Martinez, Gracia Aparecida, Barros, José Carlos, Bellesso, Marcelo, Rossato, Marina, Marret, Ana Cinira F., Chiattone, Carlos Sérgio, Hungria, Vania Tietsch de Moraes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119677/ https://www.ncbi.nlm.nih.gov/pubmed/27863757 http://dx.doi.org/10.1016/j.bjhh.2016.06.004

Ejemplares similares

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Bilateral breast plasmacytoma: a clinical case report
por: Fischer, Thais Rodrigues da Cunha, et al.
Publicado: (2016)

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
por: Silva, Luiza Soares Vieira da, et al.
Publicado: (2017)

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?()
por: Vigorito, Afonso Celso
Publicado: (2016)

Multiple myeloma and central nervous system involvement: experience of a Brazilian center
por: Dias, Ana Luiza Miranda Silva, et al.
Publicado: (2018)

Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
por: Viol Ferreira Lopes, Maricy Almeida, et al.
Publicado: (2023)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
por: Wang, Di, et al.
Publicado: (2021)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012
por: Hungria, Vânia Tietsche de Moraes, et al.
Publicado: (2013)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Stimulation of granulocytic colony formation in agar diffusion chambers implanted in cyclophosphamide pretreated mice.
por: Gordon, M. Y., et al.
Publicado: (1975)

P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
por: Wang, J.-N., et al.
Publicado: (2022)

Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates
Publicado: (1987)

Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
por: Misaki, M., et al.
Publicado: (1998)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
por: Martinez, Celia, et al.
Publicado: (2023)

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
por: Hungria, Vania, et al.
Publicado: (2023)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2021)

Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
por: Hungria, Vania, et al.
Publicado: (2020)

Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up
por: Vasquez, Jule, et al.
Publicado: (2021)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils
por: Banuelos, Jesus, et al.
Publicado: (2017)

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
por: Bota, Daniela A., et al.
Publicado: (2022)

Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
por: Togano, Tomiteru, et al.
Publicado: (2022)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I
por: Maiolino, Angelo, et al.
Publicado: (2022)

Urinary bladder hemangiosarcoma in a cat treated with partial cystectomy and adjuvant metronomic cyclophosphamide and thalidomide
por: McNally, Abigail, et al.
Publicado: (2023)

The Immunomodulating Effects of Thalidomide and Dexamethasone in a Murine Cardiac Allograft Transplantation Model
por: Kim, Soo Jin, et al.
Publicado: (2022)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
por: Choi, Jae Hee, et al.
Publicado: (2021)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pb5ne2td4r2jjk2ua1q95cb7tq